A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

920

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Neoplasms
Gastroesophageal Adenocarcinoma
Esophageal Adenocarcinoma

Interventions

DRUG: Zanidatamab
DRUG: Tislelizumab
DRUG: Trastuzumab
DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Cisplatin
DRUG: 5-Fluorouracil

Sponsor

Jazz Pharmaceuticals

Collaborators

BeOne Medicines LTD
BeOne Pharmaceutical Co., Ltd.